Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials

Author(s): Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino

Hemophilia A is an X-linked recessive hereditary bleeding disorder resulting from a deficiency in coagulation factor VIII. Difficulties due to hemophilia and its management present challenges for patient’s quality of life. Turoctocog alfa, a recombinant, B-domain truncated factor VIII, is a recent US FDA- and EMA-approved replacement therapy shown to be an effective and safe option for the treatment of individuals with hemophilia A. Data collected throughout two Phase 3, multinational, open-label, non-randomized, non-comparative trials demonstrated that individuals with hemophilia A, particularly young adults experienced improvements in healthrelated quality of life when switched from an on-demand to a prophylactic regimen of turoctocog alfa.